Search
Pipotiazine
go.drugbank.com/drugs/DB01621ApprovedInvestigationalWithdrawnPipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors8-azaguanine
go.drugbank.com/drugs/DB01667Experimental8-azaguanine is one of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesLemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigationalLemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalDuvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAvatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigationalAvatrombopag (Doptelet), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation, thereby decreasing the need for blood transfusions. Patient...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalFostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various bio...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigationalThe World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon. Tecovirimat is an antivira...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP3A InducersLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives ca...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesLandiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigationalLandiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine. It works to reduce the heart rate, myocardial contractility, and conduction v...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors